REG-PanGenomic Health Inc: PanGenomic Health Subsidiary Launches Vitamin D Health Assessments and Announces Corporate Appointments

Pangenomic HealthAnnouncement

06/07/2023 12:45

6 July 2023

 

PanGenomic Health Inc.

(“PanGenomic” or the “Company”)

 

PanGenomic Health Subsidiary Launches Vitamin D Health Assessments and
Announces Corporate Appointments

 

Vancouver, British Columbia, Canada, July 6, 2023 – PanGenomic Health Inc.
("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to
announce that its subsidiary, MUJN Diagnostics Inc. (“MUJN Diagnostics”),
has commenced a Vitamin D health assessment service and has also launched a
corporate website at mujn.ai (https://mujn.ai/).

 

"We are very excited to introduce the MUJN biomarker assessment platform at
Vancouver-based Empower Health Wellness Centre. Our first service provides
Empower Health practitioners with rapid in-clinic access to patient Vitamin D
assessments," said Vincent Lum, CEO of MUJN Diagnostics and Co-Founder of
PanGenomic Health. "Vitamin D deficiency is a global public health problem
affecting over one billion people, regardless of age, ethnicity or location.
Almost 20% of Canadians have deficient levels of Vitamin D due to cloud cover,
smog, sunscreens, or staying indoors.1”

 

Current clinical research on Vitamin D has found that:

 
* Vitamin D helps to absorb dietary calcium and phosphorus from the intestine
for use in the body for bone strength and a large variety of your body
functions.
* Vitamin D suppresses the release of parathyroid hormone, a hormone that
causes bone breakdown leading to osteoporosis.
* Vitamin D supports overall brain and other organ system health by
strengthening the immune system. 2
 

1  Nair R, Maseeh A. Vitamin D: The "sunshine" vitamin. J Pharmacol
Pharmacother. 2012 Apr;3(2):118-26. doi: 10.4103/0976-500X.95506
(https://pubmed.ncbi.nlm.nih.gov/22629085/).

Health Canada. 2016. Evidence review for dietary guidance: Technical report
2015
(https://publications.gc.ca/collections/collection_2018/sc-hc/H164-192-2016-eng.pdf).

2  Silva MC, Furlanetto TW. Intestinal absorption of vitamin D: a systematic
review. Nutr Rev. 2018 Jan 1;76(1):60-76. doi: 10.1093/nutrit/nux034
(https://academic.oup.com/nutritionreviews/article/76/1/60/4084545?login=false)

Bhattarai HK, Shrestha S, Rokka K, Shakya R. Vitamin D, Calcium, Parathyroid
Hormone, and Sex Steroids in Bone Health and Effects of Aging. J Osteoporos.
2020 Jun 17;2020:9324505. doi: 10.1155/2020/9324505
(https://www.hindawi.com/journals/jos/2020/9324505/).

Aranow C. Vitamin D and the immune system. J Investig Med. 2011
Aug;59(6):881-6. doi:10.2310/JIM.0b013e31821b8755
(https://doi.org/10.2310/JIM.0b013e31821b8755).

 

Corporate Appointments

 

The Company is pleased to announce that its Chief Technology Officer, Colin
Quon, has been appointed CTO of MUJN Diagnostics and will cease his role as
CTO of PanGenomic Health effective immediately. Mr. Quon's focus as CTO will
be on the development of the MUJN Diagnostic Support System, previously
announced by the Company on March 22, 2023.

 

The Company is also pleased to confirm that Maryam Marissen has been appointed
a Director of the Company. Ms. Marissen has been CEO of PanGenomic Health
since September 2022. Prior to joining PanGenomic Health, Ms. Marissen served
as Chief Executive Officer at Doseology Sciences from 2021-2022.

 

Maryam Marissen owns 1,000,000 stock options in the Company as at the date of
this announcement.

 

 Other Current Directorships                                        Former Directorships and/or partnerships (within the last five years)  
 PanGenomic Technologies Corp. (a subsidiary of Pangenomic Health)  Vancouver TRU Cosmetics Ltd.                                           
 TruMIND Wellness Inc.                                              Doseology Sciences Inc.                                                
 Eternal Skin Care (USA) Inc.                                                                                                              

 

Except as set out above, there is no further information regarding Maryam
Marissen that is required to be disclosed pursuant to Rule 4.9 of the AQSE
Growth Market Access Rulebook.

 

The Directors of PanGenomic Health take responsibility for this announcement.

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

 

About MUJN Diagnostics

 

MUJN Diagnostics Inc. is a wholly-owned subsidiary of PanGenomic Health Inc.
and is focused on developing a decision support system for alternative
healthcare providers. MUJN's Decision Support System will include biomarker
diagnostics, symptom and treatment tracking, and personalized health
analytics, with the goal of empowering healthcare providers and their patients
towards better outcomes.

 

About PanGenomic Health

 

PanGenomic Health is a precision health company that has developed a self-care
digital platform to deliver personalised, evidence-based information about
natural treatments. The Company’s initial focus is to support mental health.
Registered as a British Columbia benefit company, PanGenomic Health's mission
is to promote and improve the health and wellness of people and society by
providing a technology platform that identifies plant-based solutions tailored
to the health profile of each individual.

 

The Directors of PanGenomic take responsibility for this announcement.

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

 

For more information, please contact:

 

Jerry Lai, Investor Relations    Maryam Marissen, President & CEO

PanGenomic Health Inc.    PanGenomic Health Inc.

778 743 4642      778 743 4642

ir@pangenomic.com     info@pangenomic.com

 

Novum Securities Limited, AQSE Corporate Advisor

David Coffman / George Duxberry

Tel: +44 (0)207 399 9400

 

Yellow Jersey PR
Charles Goodwin / Shiv Thambirajah / Soraya Jackson
Investor Relations, UK
Tel: +44 (0)20 3004 9512

 

This news release includes certain statements that may be deemed
“forward-looking statements”, including statements respecting the services
to be provided by PanGenomic and the consideration to be paid to PanGenomic.
The use of any of the words “anticipate”, “continue”, “estimate”,
“expect”, “may”, “will”, “would”, “project”, “should”,
“believe” and similar expressions are intended to identify forward looking
statements. Although PanGenomic believes that the expectations and assumptions
on which the forward-looking statements are based are reasonable, undue
reliance should not be placed on the forward-looking statements because
PanGenomic can give no assurance that they will prove to be correct. In
particular, there is no assurance that MUJN Diagnostics and/or Psy Integrated
will be able to complete trial biomarker testing program within the timeframes
expected, or at all. Since forward-looking statements address future events
and conditions, by their very nature they involve inherent risks and
uncertainties. These statements speak only as of the date of this News
Release. Actual results could differ materially from those currently
anticipated due to a number of factors and risks including various risk
factors discussed in PanGenomic’s disclosure documents which can be found
under PanGenomic’s profile on www.sedar.com.

 

 



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved